-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationAspirin
Merck is currently developing islatravir, an anti-AIDS drug candidate that is taken orally once a month
On December 6, 2021, Eastern Time, Merck announced that it will suspend patient recruitment for two Phase III trials for the evaluation of this drug
This decision is based on the recommendation of the external data monitoring committee (eDMC) of islatravir pre-exposure prevention (PrEP) that Merck suspends the recruitment of IMPOWER 22 and IMPOWER 24 clinical trials in order to facilitate the company’s evaluation of these studies.
Regarding the suspension of this anti-AIDS drug by Merck, investors said it was not unexpected
Earlier last month, Merck stopped a Phase II clinical study called IMAGINE-DR, which raised the alarm for the safety of the drug for the first time
Another unfortunate news in the field of anti-AIDS drug research is that the pharmaceutical giant and Merck’s anti-AIDS partner Gilead also stated that out of caution, they suspended patient recruitment for a separate study that used Merck An investigational drug in a separate trial
Islatravir is one of the two core drugs of long-acting anti-HIV therapy jointly developed by Merck and Gilead.
Reference source: Merck pumps the brakes on two more PhIII trials for its lead anti-HIV drug
